



1625  
TEX4542P0403US

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application of:

Ronald J. Biediger et al.

Serial No.: 09/973,142

Filed: October 9, 2001

) Carboxylic Acid Derivatives That  
) Inhabit the Binding of Integrins  
) to Their Receptors  
)  
) Group Art Unit: 1625  
)  
) Examiner: Binta M. Robinson

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Applications  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, Virginia 22313

Sir:


Attached Form PTO/1449A lists references which were recently cited in the European counterpart application and may be considered to be material to the above-identified application by the Patent Examiner. Copies of the references are enclosed. Entry into the record is respectfully requested.

If any additional fee might be required in connection with this matter, please charge our Deposit Account No. 23-0785.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER

By

  
Martin L. Katz, Reg. No. 25,011

Date: December 15, 2004

Citicorp Center, Suite 3800  
500 West Madison Street  
Chicago, Illinois 60661-2511




TEX4542P0403US

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Mail Stop Patent Applications. Commissioner for Patents, P. O. Box 14540, Alexandria, Virginia 22313 on **December 15, 2004.**

Rebecca J. Willis  
Rebecca J. Willis



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	09/973,142
				Filing Date	October 9, 2001
				First Named Inventor	Biediger, et al.
				Group Art Unit	1625
				Examiner Name	Binta M. Robinson
Sheet	1	of	3	Attorney Docket No.	TEX4542P0403US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		EP 0 355 819	Feb. 28, 1990	Nutrasweet Co.		
		WO 99/52493	Oct. 21, 1999	Texas Biotechnology Corporation		
		WO 01/46190 A1	Jun. 28, 2001	Kyorin Seiyaku KK		
Examiner Signature					Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. <sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Comparable to Form PTO SB 08A (05-03)

Approved for use through 0731/2006 OMB 0651-0031

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

<p>Substitute for form 1413-1-100</p> <p><b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				Application Number	09/973,142
				Filing Date	October 9, 2001
				First Named Inventor	Biediger, et al.
				Group Art Unit	1625
				Examiner Name	Binta M. Robinson
Sheet	2	of	2	Attorney Docket No.	TEX4542P0403US

#### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		L. ISMAILI, ET AL.; Synthesis of New Pyrazolo(4,3-c)quinoline-3-one Derivatives and Some Oxazolo(4,5-c)quinoline-2,4-diones; Journal of Heterocyclic Chemistry, Vol. 36, No. 3, 1999, pages 719-722; France	
		J. J. PANOUSE, ET AL.; Relations structures-activities des immunomodulateurs. Apport de la modelisation moleculaire; Annales Pharmaceutiques Francaises, Vol. 58, No. 5, 2000, pages 291-302	
Examiner Signature			Date Considered

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.